Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;66(12):979-84.
doi: 10.2298/vsp0912979v.

[Laser in situ keratomyleusis (LASIK) for correction of myopia and hypermetropia--our one year experience]

[Article in Serbian]
Affiliations

[Laser in situ keratomyleusis (LASIK) for correction of myopia and hypermetropia--our one year experience]

[Article in Serbian]
Miroslav Vukosavljević et al. Vojnosanit Pregl. 2009 Dec.

Abstract

Background/aim: Laser in situ keratamileusis (LASIK) is the most commonly used refractive surgical method worldwide. The aim of this study was to examine the effectiveness and safety of LASIK in the correction of myopia and hyperopia.

Methods: The study included myopic and hyperopic eyes with preoperative best corrected visual acuity (BCVA) = 1 (20/20), of the total number of 322 divided into 2 groups--1) myopic eyes (n = 241) which were divided into 4 subgroups according to the myopia strength: a) < or = -1.75 D (n = 23), b) from -2 to -3.75 D (n = 81), c) from -4 to -6.75 D (n = 113), d) > or = -7 D (n = 24); 2) hyperopic eyes (n = 81) which were divided into 3 subgroups according to the hyperopia strength: a) < or = +1.75D (n = 10), b) from +2 to +3.75 D (n = 46), c) > or = +4 D (n = 25). Myopic and hyperopic eyes with preoperative BCVA < or = 0.9 (eyes with ambliopia) were excluded from the study, as well as eyes with astigmatism > 1.5 D. To assess the effectiveness of LASIK we examined the percentage of eyes in the mentioned subgroups, which derived uncorrected visual acuity (UCVA) 6 month after the intervention to the following: a) UCVA = 1 (20/20) and b) UCVA > or = 0.5 (20/40). To assess the safety of LASIK we examined the frequency of intraoperative and postoperative complications. A prospective study was performed in a 6-months follow-up period. RESULTS. Refractive spherical equivalent (RSE) of myopic eyes was in the range from -0.75 D to -12 D. In the first subgroup preoperative mean value of RSE with standard deviation (mean RSE +/- SD) was -1.39 +/- 0.36 D, and 6 months after the LASIK 100% of the eyes had UCVA = 20/20. In the second subgroup preoperative mean RSE +/- SD was -2.85 +/- 0.50 D, and 6 months after LASIK 93% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the third subgroup preoperative mean RSE +/- SD was -5.03 +/- 0.75 D, and 6 months after the LASIK 90% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the fourth subgroup preoperative mean RSE +/- SD was -7.68 +/- 1.03 D, and 6 months after the LASIK 96% of the eyes had UCVA = 20/20, but 100% of eyes had UCVA > or = 20/40. Refractive spherical equivalent of hyperopic eyes was in the range from +1 D to +6 D. In the first subgroup preoperative mean RSE +/- SD was +1.50 +/- 0.30 D, and 6 months after the LASIK 90% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In the second subgroup preoperative mean RSE +/- SD was +2.65 +/- 0.46 D, and 6 months after the LASIK 87% of the eyes had UCVA = 20/20, but 96% of the eyes had UCVA > or = 20/40. In the third subgroup preoperative mean RSE +/- SD was +4.62 +/- 0.68 D, and 6 months after the LASIK 64% of the eyes had UCVA = 20/20, but 100% of the eyes had UCVA > or = 20/40. In our study intraoperative complications appeared in 6 eyes (1.86%): thin flap in 2 eyes (0.62%) and epithelial defects in 4 eyes (1.24%), yet postoperative complications appeared in 10 eyes (3.10%): flap folds in 2 eyes (0.62%), epithelial ingrowth in 4 eyes (1.24%) and regression in 4 eyes (1.24%).

Conclusion: LASIK is effective and safe refractive surgical method for correcting myopia up to -12 D and hyperopia up to +6 D.

PubMed Disclaimer

Similar articles

Publication types